Author:
Goh Yun Shan,Fong Siew-Wai,Tay Matthew Zirui,Rouers Angeline,Chang Zi Wei,Chavatte Jean-Marc,Hor Pei Xiang,Loh Chiew Yee,Huang Yuling,Tan Yong Jie,Wang Bei,Ngoh Eve Zi Xian,Mohd Salleh Siti Nazihah,Lee Raphael Tze Chuen,Lim Georgina,Yu Jocelyn Jin,Soh Zheng Kuang,Chin Yi Qing,Lim Jonathan Jordon,Ongko Juwinda,Libau Eshele Anak,Abdullah Mohammed Ridzwan Bin,Diong Shiau Hui,Teo Jefanie,Yeo He Ping,Chua Adeline C. Y.,Torres-Ruesta Anthony,Amrun Siti Naqiah,Yeo Nicholas Kim-Wah,Neo Vanessa Kexin,Chen Wendy Yehui,Kam Isaac Kai Jie,Ong Alice Soh Meoy,Goh Estelle Yi Wei,Wong Nathan,Lim Zhi Feng Sherman,Maurer-Stroh Sebastian,Wang Cheng-I,Leo Yee‐Sin,Lin Raymond T. P.,Lam Meng Chon,Lye David C.,Young Barnaby Edward,Ng Lisa F. P.,Renia Laurent, ,
Abstract
AbstractIdentification of the risk factors and the high-risk groups which are most vulnerable is critical in COVID-19 disease management at a population level. Evaluating the efficacy of vaccination against infections is necessary to determine booster vaccination strategies for better protection in high-risk groups. In this study, we recruited 158 mRNA-vaccinated individuals during the Delta wave of SARS-CoV-2 infections in Singapore and examined the antibody profiles of infected individuals. We found that, despite high exposure due to communal living conditions in proximity, 4% of individuals (6/158) had PCR-confirmed infections and 96% (152/158) remained uninfected. Time-course analysis of the antibody profile at the start and the end of quarantine period showed Delta-specific boosting of anti-spike antibody response in 57% of the uninfected individuals (86/152). In the remaining 43% of the uninfected individuals (66/152) with no Delta-specific antibody boost, we found a higher Delta-specific antibody response at the start of quarantine period, which correlated with higher Delta pseudovirus neutralizing capacity. Our findings indicate that a higher basal variant-specific antibody response in the mRNA-vaccinated individuals contributes to better protection against infections by the new emerging SARS-CoV-2 variants.
Funder
Agency for Science, Technology and Research (A*STAR), Singapore
Singapore National Medical Research Council
U.S. Food and Drug Administration
Publisher
Springer Science and Business Media LLC